Please turn JavaScript on
GEN – Genetic Engineering and Biotechnology News icon

GEN – Genetic Engineering and Biotechnology News

Following GEN – Genetic Engineering and Biotechnology News's news feed is very easy. Subscribe using the "follow" button on the top right and if you want to, choose the updates by topic or tag.

We will deliver them to your inbox, your phone, or you can use follow.it like your own online RSS reader. You can unsubscribe whenever you want with one click.

Keep up to date with GEN – Genetic Engineering and Biotechnology News!

GEN – Genetic Engineering and Biotechnology News: GEN Homepage - GEN - Genetic Engineering and Biotechnology News

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  4.43 / day

Message History

Once labeled the “disease of kings” because of its association with consuming rich foods and alcohol, gout has emerged as a royal pain to a growing number of people. A 2024 study showed the prevalence of the most common form of inflammatory arthritis jumping 22.5% between 1990 and 2020, to 55.8 million people worldwide, with 95.8 million projected by 2050. An aging population...


Read full story

High-resolution extracellular electrophysiology is typically used to record from neurons in order to understand brain function. Combining electrophysiology with optogenetics allows researchers to test the causal role of specific neurons by activating or inactivating those populations while recording the effects of neural activity.


Read full story

The 2030 patent cliff may either decimate revenue streams or provide an opportunity for innovation that can transform the biopharmaceutical industry. As it stands today, some 200 biopharmaceuticals are scheduled to go off patent during the next four years, representing approximately $300 billion in revenue.

That revenue hit can be softened if biopha...


Read full story

Some of the forces that shape biopharma cluster development are constants year after year, such as the emergence of startups from university and research institute labs to develop new treatments, thanks to ideas backed by the brains of researchers and executives, and the bucks of serial entrepreneurs and other investors.

But in recent years, several additional unique c...


Read full story

Erik Terjesen
Managing Director
Silicon Foundry, a Kearney Company

Clinical development has become the most resource-intensive stage of drug innovation. Across the industry,


Read full story